得克萨斯州现在首次提供经林业发展局批准的家庭宫颈癌检测,增加了服务不足地区获得服务的机会。 Texas now offers first FDA-approved at-home cervical cancer test, boosting access in underserved areas.

德克萨斯州现在可以使用第一个FDA批准的家庭宫癌查,由Teal Health开发,将于2025年10月推出,成为加入该计划的第八个州. Texans can now use the first FDA-approved at-home cervical cancer screening, developed by Teal Health, available in October 2025 as the eighth state to join the rollout. 该测试使用类似卫生棉条的设备在家中采集样本,检测高危险HPV菌株,与办公室内筛查一样准确。 The test, which uses a tampon-like device to collect a sample at home, detects high-risk HPV strains and is as accurate as in-office screenings. 它要求对资格和结果审查进行远程医疗访问,工具包费用为99美元,未投保病人的费用总额约为249美元。 It requires a telehealth visit for eligibility and results review, with the kit costing $99 and total costs around $249 for uninsured patients. 该方案旨在改善农村和服务不足地区的覆盖率,尽管宫颈癌可通过早期检测预防,但检查率仍然很低。 The program aims to improve access in rural and underserved areas, where screening rates remain low despite cervical cancer being preventable with early detection. 现有大约4万人的全国等待名单,计划于2026年扩大到所有各州。 A national waitlist of about 40,000 people exists, with expansion to all states planned by 2026.